223 related articles for article (PubMed ID: 8613910)
21. 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist.
Yasuda Y; Kikuchi T; Suzuki S; Tsutsui M; Yamada K; Hiyama T
Life Sci; 1988; 42(20):1941-54. PubMed ID: 3130534
[TBL] [Abstract][Full Text] [Related]
22. The preovulatory prolactin surge: an evaluation of the role of dopamine.
Arbogast LA; Ben-Jonathan N
Endocrinology; 1988 Dec; 123(6):2690-5. PubMed ID: 3264239
[TBL] [Abstract][Full Text] [Related]
23. Not only dopamine D2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia.
Wang D; Wong HK; Zhang L; McAlonan GM; Wang XM; Sze SC; Feng YB; Zhang ZJ
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):332-8. PubMed ID: 22796279
[TBL] [Abstract][Full Text] [Related]
24. Effect of mesulergine on prolactin secretion and dopamine D2 receptors-adaptive changes in diethylstilbestrol-induced hyperplasia of the rat anterior pituitary.
Pisarek H; Stepien H; Pawlikowski M
Endocr Regul; 1992 Mar; 26(1):17-22. PubMed ID: 1421203
[TBL] [Abstract][Full Text] [Related]
25. Antipsychotic drugs inhibit prolactin release from rat anterior pituitary cells in culture by a mechanism not involving the dopamine receptor.
West B; Dannies PS
Endocrinology; 1979 Apr; 104(4):877-80. PubMed ID: 436760
[TBL] [Abstract][Full Text] [Related]
26. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
[TBL] [Abstract][Full Text] [Related]
27. The environmental estrogen bisphenol A stimulates prolactin release in vitro and in vivo.
Steinmetz R; Brown NG; Allen DL; Bigsby RM; Ben-Jonathan N
Endocrinology; 1997 May; 138(5):1780-6. PubMed ID: 9112368
[TBL] [Abstract][Full Text] [Related]
28. Intraventricular administration of histidyl-proline-diketopiperazine [Cyclo(His-Pro)] suppresses prolactin secretion and synthesis: a possible role of Cyclo(His-Pro) as dopamine uptake blocker in rat hypothalamus.
Jikihara H; Ikegami H; Koike K; Wada K; Morishige K; Kurachi H; Hirota K; Miyake A; Tanizawa O
Endocrinology; 1993 Mar; 132(3):953-8. PubMed ID: 7679984
[TBL] [Abstract][Full Text] [Related]
29. Estradiol induces expression of 5-hydroxytryptamine (5-HT) 4, 5-HT5, and 5-HT6 receptor messenger ribonucleic acid in rat anterior pituitary cell aggregates and allows prolactin release via the 5-HT4 receptor.
Papageorgiou A; Denef C
Endocrinology; 2007 Mar; 148(3):1384-95. PubMed ID: 17122082
[TBL] [Abstract][Full Text] [Related]
30. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
Bartoszyk GD; Harting J; Minck KO
J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
[TBL] [Abstract][Full Text] [Related]
31. Hyperprolactinemia exerts a negative effect on the beta-endorphin content of the rat neurointermediate pituitary lobe.
Lamberts SW; Uitterlinden P; Bons EG; Zuiderwijk JM; Verleun T; Oosterom R; Hackeng WH
Endocrinology; 1984 Jun; 114(6):2349-53. PubMed ID: 6327244
[TBL] [Abstract][Full Text] [Related]
32. Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain.
Semba J; Watanabe A; Kito S; Toru M
Neuropharmacology; 1995 Jul; 34(7):785-91. PubMed ID: 8532145
[TBL] [Abstract][Full Text] [Related]
33. Ethanol and estradiol modulate alternative splicing of dopamine D2 receptor messenger RNA and abolish the inhibitory action of bromocriptine on prolactin release from the pituitary gland.
Oomizu S; Boyadjieva N; Sarkar DK
Alcohol Clin Exp Res; 2003 Jun; 27(6):975-80. PubMed ID: 12824819
[TBL] [Abstract][Full Text] [Related]
34. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum.
Inoue A; Miki S; Seto M; Kikuchi T; Morita S; Ueda H; Misu Y; Nakata Y
Eur J Pharmacol; 1997 Feb; 321(1):105-11. PubMed ID: 9083792
[TBL] [Abstract][Full Text] [Related]
35. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.
Dahan L; Husum H; Mnie-Filali O; Arnt J; Hertel P; Haddjeri N
J Psychopharmacol; 2009 Mar; 23(2):177-89. PubMed ID: 18515444
[TBL] [Abstract][Full Text] [Related]
36. The inhibition of phosphatidylinositol turnover: a possible postreceptor mechanism for the prolactin secretion-inhibiting effect of dopamine.
Canonico PL; Valdenegro CA; MacLeod RM
Endocrinology; 1983 Jul; 113(1):7-14. PubMed ID: 6861715
[TBL] [Abstract][Full Text] [Related]
37. Ethanol induces hyperprolactinemia by increasing prolactin release and lactotrope growth in female rats.
De A; Boyadjieva N; Oomizu S; Sarkar DK
Alcohol Clin Exp Res; 2002 Sep; 26(9):1420-9. PubMed ID: 12351938
[TBL] [Abstract][Full Text] [Related]
38. The effect of aripiprazole on prepulse inhibition of the startle response in normal and hyperdopaminergic states in rats.
Nakai S; Hirose T; Mori T; Stark A; Araki H; Kikuchi T
Int J Neurosci; 2008 Jan; 118(1):39-57. PubMed ID: 18041605
[TBL] [Abstract][Full Text] [Related]
39. Neuroendocrine profile of SDZ HDC-912 and OPC-4392, two new atypical antipsychotic drugs, in schizophrenic patients.
Duval F; Mokrani MC; Macher JP; Crocq MA; Castro JO; Bailey P; Lataste X
Psychopharmacology (Berl); 1993; 110(1-2):177-80. PubMed ID: 7870880
[TBL] [Abstract][Full Text] [Related]
40. Slow dissociation of partial agonists from the D₂ receptor is linked to reduced prolactin release.
Carboni L; Negri M; Michielin F; Bertani S; Fratte SD; Oliosi B; Cavanni P
Int J Neuropsychopharmacol; 2012 Jun; 15(5):645-56. PubMed ID: 21733233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
